Compare VIK & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIK | IQV |
|---|---|---|
| Founded | 1997 | 1982 |
| Country | Bermuda | United States |
| Employees | N/A | 93000 |
| Industry | | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6B | 35.1B |
| IPO Year | 2023 | 2013 |
| Metric | VIK | IQV |
|---|---|---|
| Price | $85.79 | $263.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 16 |
| Target Price | $84.14 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 3.6M | 1.2M |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $14.41 | $6.77 |
| Revenue Next Year | $14.16 | $5.89 |
| P/E Ratio | ★ $37.68 | $160.47 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $56.37 | $154.50 |
| 52 Week High | $110.09 | $265.25 |
| Indicator | VIK | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 31.73 | 71.48 |
| Support Level | $68.14 | $159.91 |
| Resistance Level | $87.00 | N/A |
| Average True Range (ATR) | 3.76 | 7.43 |
| MACD | -1.18 | -0.35 |
| Stochastic Oscillator | 6.95 | 96.60 |
Viking Holdings Ltd is a travel company, with a fleet of 92 small ships, which view as floating hotels. It offers travel experiences on all seven continents in all three categories of the cruise industry river, ocean, and expedition cruising. The Group defines its products based on the type of cruise offering and language of the cruise service. The River segment provides river cruises outside the United States to English-speaking passengers. The Ocean segment offers ocean cruises to English-speaking passengers. Other include operating segments that are not individually reportable, consisting of expedition cruises for English-speaking passengers (Expedition), Mississippi River cruises for English-speaking passengers, and Viking China, which includes cruises for Mandarin.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.